The advantage of WES/WTS with the focus of a targeted panel

 

Sema4 Signal PanCancer integrates tumor-normal matched whole exome sequencing (WES) with whole transcriptome sequencing (WTS) in one comprehensive test to rapidly deliver insights on over 2,000 of the most clinically relevant and actionable cancer genes.*

 

Compared with running multiple sequential panels, Sema4 Signal PanCancer provides:

More information, faster TAT, smaller sample size, lower cost,

reduced administrative burden, and a single comprehensive report

WES (DNA)

  • Reports insights on ~2,200 of the most relevant cancer genes
  • Tumor-normal matching helps distinguish somatic and germline variants
  • The gold standard method for measuring tumor mutational burden (TMB)
  • Captures data from ~18,500 genes

WTS (RNA)

    • Provides information on gene fusions and splice variants to help define molecular signatures, stratify risk, and inform the use of targeted therapies

 

 

WES + WTS

By pairing WES with WTS, Sema4 provides information that meets the current and future needs of cancer patients, enabling their providers to identify therapies and clinical trials today and take advantage of those of tomorrow. We employ tumor-normal matching to provide information on germline contributions, which can inform treat,net in a significant proportion of advanced cancer patients. Read more about our advanced technologies.

Sema4 Signal WES/WTS and PanCancer can detect >99% of mutations associated with FDA-approved therapies, standard-of-care treatments, and investigational therapies in clinical trials

 

Do you need information on more than 2,200 genes?

Consider Sema4 Signal WES/WTS:

Molecular profiling of 18,500 genes >>

 

Sema4 Signal PanCancer can help providers

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Determine diagnoses and prognoses

      • Detects alterations including single nucleotide variants (SNVs), insertions and deletions (InDels), copy number variants (CNVs), arm-length aneuploidies, and RNA splice variants and fusions
      • Analyzes immuno-oncology biomarkers, including PD-L1, DNA mismatch repair (MMR), microsatellite instability (MSI), and TMB

 

Seamlessly access testing

      • Workflow integration (EMR, Sema4 Provider Portal)
      • Genetic counseling for all non-negative germline findings
      • Broad network coverage, supportive billing policies
      • Sample coordination services
      • Learn more about our somatic testing support services

 

Identify available targeted therapies

      • Clinically actionable findings are presented on the first page of the easy-to-read results report
      • Can identify variants not picked up by targeted panels, to inform decisions for patients for whom standard treatment has failed

 

Identify suitable clinical trials

      • Current trials are outlined in the comprehensive results report
      • Emphasis on trials at the provider’s institution
      • By combining somatic testing with Sema4 Signal informatics tools, providers can leverage real-world data to enable advanced trial matching

 

Discover hereditary cancer contributions

      • Germline findings may inform treatment and management, including whether a patient qualifies for PARP inhibitors
      • Further testing can be done with Sema4 Signal Hereditary Cancer

 

WES/WTS and PanCancer Interactive Lookup Tool

Find information on specific cancer genes included in our WES/WTS and PanCancer tests

 

Resources

 

 

Connect with us today

Kindly fill out the form below and we’ll schedule a time to discuss your needs. Or feel free to call us at 833-486-6260.
 



* Genes selected for inclusion based on large publicly available datasets, current understanding of the genomic landscape of somatic changes in solid tumors and hematological malignancies, competitors’ platforms, and novel content for predicting prognosis and disease progression.

NCCN guidelines: Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Guideline Name V.X.2019. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed January 10, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility of their application or use in any way.